Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 16/20 | 0.64 |
| ▸ | NTSR2 | O95665 | 7/20 | 0.62 |
| ▸ | SORT1 | Q99523 | 5/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30623611 | 0.98 | NTSR1 (0.65) | NTSR1NTSR2SORT1OPRM1OPRD1 | |
| SCHEMBL31151633 | 0.97 | NTSR1 (0.61) | NTSR1NTSR2SORT1OPRM1OPRD1 | |
| SCHEMBL29414469 | 0.97 | NTSR1 (0.62) | NTSR1NTSR2SORT1OPRM1OPRD1 | |
| SCHEMBL30361896 | 0.97 | NTSR1 (0.61) | NTSR1NTSR2SORT1OPRM1OPRD1 | |
| SCHEMBL30361957 | 0.96 | NTSR1 (0.60) | NTSR1NTSR2SORT1OPRM1OPRD1 | |
| SCHEMBL29940473 | 0.96 | NTSR1 (0.64) | NTSR1NTSR2SORT1OPRM1OPRD1 | |
| SCHEMBL30361923 | 0.96 | NTSR1 (0.60) | NTSR1NTSR2SORT1OPRM1OPRD1 | |
| SCHEMBL29894426 | 0.95 | NTSR1 (0.63) | NTSR1NTSR2SORT1OPRM1OPRD1 | |
| SCHEMBL30361837 | 0.94 | NTSR1 (0.61) | NTSR1NTSR2SORT1OPRM1OPRD1 | |
| SCHEMBL30974461 | 0.93 | SLC6A2 (0.58) | NTSR1NTSR2SORT1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713002-A1 | PEPTIDES FOR USE IN THE TREATMENT OF SARCOMA | Forssmann, Wolf-Georg (DE) | 2026-03-25 | — | — | EP | claimed |
| EP-4501348-A1 | PEPTIDES FOR USE IN THE IMPROVEMENT OF WELL-BEING | Forssmann, Wolf-Georg (DE) | 2025-02-05 | — | — | EP | claimed |
| EP-4501347-A1 | PEPTIDES FOR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Forssmann, Wolf-Georg (DE) | 2025-02-05 | — | — | EP | claimed |
| WO-2024235986-A1 | PEPTIDES FOR USE IN THE TREATMENT OF SARCOMA | PHARIS BIOTEC GMBH (DE) | 2024-11-21 | — | — | WO | claimed |
| EP-4713002-A1 | PEPTIDES FOR USE IN THE TREATMENT OF SARCOMA | Forssmann, Wolf-Georg (DE) | 2026-03-25 | — | — | EP | disclosed |
| EP-4713002-A1 | PEPTIDES FOR USE IN THE TREATMENT OF SARCOMA | Forssmann, Wolf-Georg (DE) | 2026-03-25 | — | — | EP | disclosed |
| WO-2025114560-A1 | ALB408-423 PEPTIDES FOR USE IN THE TREATMENT OF CANCER IN COMBINATION WITH RADIOTHERAPY | PHARIS BIOTEC GMBH (DE) | 2025-06-05 | — | — | WO | disclosed |
| WO-2025114560-A1 | ALB408-423 PEPTIDES FOR USE IN THE TREATMENT OF CANCER IN COMBINATION WITH RADIOTHERAPY | PHARIS BIOTEC GMBH (DE) | 2025-06-05 | — | — | WO | disclosed |
| EP-3877396-B1 | POLYPEPTIDES FOR THE TREATMENT OF CANCER | NEOPEP PHARMA GMBH & CO KG (DE) | 2025-02-19 | — | — | EP | disclosed |
| EP-4501348-A1 | PEPTIDES FOR USE IN THE IMPROVEMENT OF WELL-BEING | Forssmann, Wolf-Georg (DE) | 2025-02-05 | — | — | EP | disclosed |
| EP-4501348-A1 | PEPTIDES FOR USE IN THE IMPROVEMENT OF WELL-BEING | Forssmann, Wolf-Georg (DE) | 2025-02-05 | — | — | EP | disclosed |
| EP-4501347-A1 | PEPTIDES FOR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Forssmann, Wolf-Georg (DE) | 2025-02-05 | — | — | EP | disclosed |
| EP-4501347-A1 | PEPTIDES FOR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Forssmann, Wolf-Georg (DE) | 2025-02-05 | — | — | EP | disclosed |
| WO-2024235986-A1 | PEPTIDES FOR USE IN THE TREATMENT OF SARCOMA | PHARIS BIOTEC GMBH (DE) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024235986-A1 | PEPTIDES FOR USE IN THE TREATMENT OF SARCOMA | PHARIS BIOTEC GMBH (DE) | 2024-11-21 | — | — | WO | disclosed |
| US-20230173076-A1 | METABOLICALLY STABLE PEPTIDE ANALOGS | UNIV STRASBOURG (FR) | 2023-06-08 | — | — | US | disclosed |
| CN-105530948-B | Peptides having antagonistic activity against natural CXCR4 | 法瑞斯生物技术有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20230068834-A1 | SCAFFOLD PROTEINS AND THERAPEUTIC NANOCONJUGATES BASED ON NIDOGEN | FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU (ES) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173076-A1 | METABOLICALLY STABLE PEPTIDE ANALOGS | GPR119, GLP1R, GIPR | NTSR1 35/4885NTSR2 27/4885SORT1 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.